XML 80 R69.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value (Details) - USD ($)
$ / shares in Units, $ in Millions
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Fair Value (Details) [Line Items]    
Notes payable based on closing price (in Dollars per share) $ 6.83 $ 9.01
Fair value amortized cost $ 18.2  
Convertible notes payable 13.6  
Embedded conversion feature 4.6  
Fair value of the convertible notes payable $ 2.0  
Warrants to purchase common stock (in Shares) 2,407,500  
Additional warrant to purchase estimated shares (in Shares) 86,679  
Series of Individually Immaterial Business Acquisitions [Member]    
Fair Value (Details) [Line Items]    
Contingent earn-out, description Pursuant to the Merger Agreement, Clene Nanomedicine’s common shareholders immediately prior to the Reverse Recapitalization and Initial Shareholders of Tottenham were entitled to receive additional shares of up to 8,333,333 shares and 750,000 shares of Common Stock, respectively, upon us achieving certain milestones (see Note 3). Upon the consummation of the Reverse Recapitalization, Clene Nanomedicine and the Initial Shareholders are entitled to receive up to 8,346,185 additional shares as a result of the exercise of the stock options in November 2020, and 750,000 shares of Common Stock  
Avenue Loan [Member]    
Fair Value (Details) [Line Items]    
Warrants to purchase common stock (in Shares) 115,851